PTPN22 - Wiki-Pi

Search Results for: PTPN22

Can't find the interaction you're looking for? Try the advanced search

19 interactions involving PTPN22 - protein tyrosine phosphatase non-receptor type 22 found:

Sort by: Symbol Number of Pathways Number of Drugs Number of Diseases

Novel	Symbol	Description	Pathways Hide	Drugs Hide	Diseases Hide
Novel	GSTP1	glutathione S-transferase pi 1	Glutathione conjugation Detoxification of Reactive Oxygen Species Neutrophil degranulation Paracetamol ADME	Glutathione Troglitazone Clozapine Etacrynic acid Clomipramine (9R,10R)-9-(S-glutathionyl)-10-hydroxy-9,10-dihydrophenanthrene S-Hydroxycysteine Cibacron Blue Glutathione sulfonic acid Glutathione disulfide Deoxycholic acid Deoxycholic acid S-(4-nitrobenzyl)glutathione 2-(N-morpholino)ethanesulfonic acid S-Hexylglutathione Canfosfamide Ezatiostat Exisulind S-NONYL-CYSTEINE S-(4-BROMOBENZYL)CYSTEINE Curcumin Dinitrochlorobenzene Hypericin Curcumin sulfate	Prostate cancer
Novel	HMGCS2	3-hydroxy-3-methylglutaryl-CoA synthase 2	PPARA activates gene expression Synthesis of Ketone Bodies Mitochondrial protein degradation		HMG-CoA synthase (HMGCS) deficiency
Novel	ING4	inhibitor of growth family member 4	HATs acetylate histones
Novel	NOTCH2	notch receptor 2	Pre-NOTCH Processing in the Endoplasmic Reticulum Pre-NOTCH Transcription and Translation Pre-NOTCH Processing in Golgi Pre-NOTCH Processing in Golgi NOTCH2 intracellular domain regulates transcription NOTCH2 intracellular domain regulates transcription NOTCH2 Activation and Transmission of Signal to the Nucleus NOTCH2 Activation and Transmission of Signal to the Nucleus Notch-HLH transcription pathway Defective LFNG causes SCDO3 NOTCH4 Intracellular Domain Regulates Transcription		Alagille syndrome Hajdu-Cheney syndrome Type II diabetes mellitus
Novel	SARS1	seryl-tRNA synthetase 1	Selenocysteine synthesis Cytosolic tRNA aminoacylation	Serine
Novel	WARS2	tryptophanyl tRNA synthetase 2, mitochondrial	Mitochondrial tRNA aminoacylation	Tryptophan
	CBL	Cbl proto-oncogene	Interleukin-6 signaling Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants Spry regulation of FGF signaling Regulation of KIT signaling EGFR downregulation TGF-beta receptor signaling activates SMADs Constitutive Signaling by EGFRvIII Negative regulation of FGFR1 signaling Negative regulation of FGFR2 signaling Negative regulation of FGFR3 signaling Negative regulation of FGFR4 signaling Negative regulation of MET activity PTK6 Regulates RTKs and Their Effectors AKT1 and DOK1 Cargo recognition for clathrin-mediated endocytosis Clathrin-mediated endocytosis InlB-mediated entry of Listeria monocytogenes into host cell InlB-mediated entry of Listeria monocytogenes into host cell Regulation of signaling by CBL Regulation of signaling by CBL Signaling by CSF1 (M-CSF) in myeloid cells Negative regulation of FLT3 FLT3 signaling by CBL mutants		Noonan syndrome and related disorders, including: Noonan syndrome (NS); Leopard syndrome (LS); Noonan syndrome-like with loose anagen hair (NS/LAH); CBL-mutation associated syndrome (CBL); Neurofibromatosis type 1 (NF1); Neurofibromatosis type 2 (NF2); Neurofibromatosis-Noonan syndrome (NFNS); Legius syndrome; Cardiofaciocutaneous syndrome (CFCS); Costello syndrome (CS)
	CD247	CD247 molecule		Muromonab Teclistamab Odronextamab
	CD3E	CD3 epsilon subunit of T-cell receptor complex	Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell Downstream TCR signaling Phosphorylation of CD3 and TCR zeta chains Translocation of ZAP-70 to Immunological synapse Generation of second messenger molecules Co-inhibition by PD-1	Muromonab Teplizumab Catumaxomab Mosunetuzumab Teclistamab Odronextamab	T-B+Severe combined immunodeficiencies (SCIDs), including the following eight diseases: X-linked SCID; Janus kinase-3 (Jak3) deficiency; IL-7 receptor alpha (IL7R alpha) deficiency; IL-2 receptor alpha (IL2R alpha) deficiency; CD45 deficiency; CD3 deficiency; Winged Helix Nude (WHN) deficiency; Immunodeficiency with thynoma
	CLK1	CDC like kinase 1		Debromohymenialdisine CHGN111 ethyl 3-[(E)-2-amino-1-cyanoethenyl]-6,7-dichloro-1-methyl-1H-indole-2-carboxylate Fostamatinib
	CRK	CRK proto-oncogene, adaptor protein	ARMS-mediated activation ARMS-mediated activation Downstream signal transduction Regulation of actin dynamics for phagocytic cup formation p130Cas linkage to MAPK signaling for integrins VEGFA-VEGFR2 Pathway PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases MET activates RAP1 and RAC1 MET receptor recycling Regulation of signaling by CBL FCGR3A-mediated phagocytosis
	CSK	C-terminal Src kinase	GAB1 signalosome Phosphorylation of CD3 and TCR zeta chains Integrin signaling Co-inhibition by PD-1 MAP2K and MAPK activation Signaling by moderate kinase activity BRAF mutants Signaling by high-kinase activity BRAF mutants Signaling by BRAF and RAF1 fusions Paradoxical activation of RAF signaling by kinase inactive BRAF RHOH GTPase cycle Signaling downstream of RAS mutants Signaling by RAF1 mutants Negative regulation of FLT3	Dasatinib Staurosporine TG-100801 Fostamatinib
	EGFR	epidermal growth factor receptor	Signaling by ERBB2 Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants Signaling by ERBB4 SHC1 events in ERBB2 signaling SHC1 events in ERBB2 signaling PLCG1 events in ERBB2 signaling PIP3 activates AKT signaling Signaling by EGFR GRB2 events in EGFR signaling GAB1 signalosome SHC1 events in EGFR signaling EGFR downregulation GRB2 events in ERBB2 signaling PI3K events in ERBB2 signaling EGFR interacts with phospholipase C-gamma EGFR Transactivation by Gastrin Constitutive Signaling by Aberrant PI3K in Cancer Signal transduction by L1 Constitutive Signaling by EGFRvIII Inhibition of Signaling by Overexpressed EGFR RAF/MAP kinase cascade ERBB2 Regulates Cell Motility PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling ERBB2 Activates PTK6 Signaling Cargo recognition for clathrin-mediated endocytosis Clathrin-mediated endocytosis PTK6 promotes HIF1A stabilization Downregulation of ERBB2 signaling TFAP2 (AP-2) family regulates transcription of growth factors and their receptors Extra-nuclear estrogen signaling NOTCH3 Activation and Transmission of Signal to the Nucleus HCMV Early Events Estrogen-dependent nuclear events downstream of ESR-membrane signaling Signaling by ERBB2 KD Mutants Signaling by ERBB2 ECD mutants Signaling by ERBB2 TMD/JMD mutants Respiratory syncytial virus (RSV) attachment and entry Developmental Lineage of Mammary Gland Myoepithelial Cells	Cetuximab Lidocaine Gefitinib Erlotinib Lapatinib Panitumumab Alvocidib IGN311 Matuzumab Vandetanib Rindopepimut Canertinib Pelitinib Varlitinib AV-412 S-{3-[(4-ANILINOQUINAZOLIN-6-YL)AMINO]-3-OXOPROPYL}-L-CYSTEINE PD-168393 Afatinib Osimertinib Necitumumab Foreskin keratinocyte (neonatal) Depatuxizumab mafodotin Icotinib Neratinib Dacomitinib Fostamatinib Poziotinib Zalutumumab Brigatinib Olmutinib Zanubrutinib Abivertinib Mobocertinib Almonertinib Amivantamab	Laryngeal cancer Cervical cancer Oral cancer Gastric cancer Choriocarcinoma Esophageal cancer Glioma Bladder cancer
	GRB2	growth factor receptor bound protein 2	Interleukin-15 signaling Interleukin-15 signaling Signaling by CSF3 (G-CSF) Signaling by CSF3 (G-CSF) STAT5 activation downstream of FLT3 ITD mutants Signaling by FLT3 ITD and TKD mutants Signaling by FLT3 ITD and TKD mutants Signaling by ALK fusions and activated point mutants Signaling by LTK	Pegademase 4-[(10s,14s,18s)-18-(2-Amino-2-Oxoethyl)-14-(1-Naphthylmethyl)-8,17,20-Trioxo-7,16,19-Triazaspiro[5.14]Icos-11-En-10-Yl]Benzylphosphonic Acid
	LCK	LCK proto-oncogene, Src family tyrosine kinase	GPVI-mediated activation cascade PIP3 activates AKT signaling Signaling by SCF-KIT Signaling by SCF-KIT Regulation of KIT signaling Nef and signal transduction Nef Mediated CD4 Down-regulation Downstream TCR signaling Phosphorylation of CD3 and TCR zeta chains Translocation of ZAP-70 to Immunological synapse Generation of second messenger molecules PECAM1 interactions Constitutive Signaling by Aberrant PI3K in Cancer DAP12 signaling DAP12 signaling Co-stimulation by CD28 CD28 dependent PI3K/Akt signaling CD28 dependent Vav1 pathway Co-inhibition by CTLA4 Co-inhibition by PD-1 PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling RHOH GTPase cycle Interleukin-2 signaling Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants FLT3 signaling through SRC family kinases	Dasatinib AP-22408 Staurosporine 1-Tert-Butyl-3-(4-Chloro-Phenyl)-1h-Pyrazolo[3,4-D]Pyrimidin-4-Ylamine {4-[(2S)-2-Acetamido-3-({(1S)-1-[3-carbamoyl-4-(cyclohexylmethoxy)phenyl]ethyl}amino)-3-oxopropyl]-2-phosphonophenoxy}acetic acid Phosphoaminophosphonic Acid-Adenylate Ester 3-(2-AMINOQUINAZOLIN-6-YL)-4-METHYL-N-[3-(TRIFLUOROMETHYL)PHENYL]BENZAMIDE 2,3-DIPHENYL-N-(2-PIPERAZIN-1-YLETHYL)FURO[2,3-B]PYRIDIN-4-AMINE 5,6-DIPHENYL-N-(2-PIPERAZIN-1-YLETHYL)FURO[2,3-D]PYRIMIDIN-4-AMINE N-(2-chlorophenyl)-5-phenylimidazo[1,5-a]pyrazin-8-amine N-(2,6-dimethylphenyl)-5-phenylimidazo[1,5-a]pyrazin-8-amine N-(2-chloro-6-methylphenyl)-8-[(3S)-3-methylpiperazin-1-yl]imidazo[1,5-a]quinoxalin-4-amine Ponatinib Nintedanib Fostamatinib Zanubrutinib Zotiraciclib	Combined immunodeficiencies (CIDs), including the following nine diseases: X-linked hyper IgM syndrome; CD40 deficiency hyper IgM syndrome; Purine nucleoside phosphorylase (PNP) deficiency; Omenn syndrome; MHC deficiency (HLA-class I); MHC deficiency (HLA-class II); Zap-70 deficiency; p56 Lck deficiency; CD8 deficiency
	PRKCD	protein kinase C delta	Apoptotic cleavage of cellular proteins Calmodulin induced events Effects of PIP2 hydrolysis SHC1 events in ERBB2 signaling DAG and IP3 signaling Role of phospholipids in phagocytosis G alpha (z) signalling events HuR (ELAVL1) binds and stabilizes mRNA VEGFR2 mediated cell proliferation CLEC7A (Dectin-1) signaling RHO GTPases Activate NADPH Oxidases Neutrophil degranulation Interferon gamma signaling KEAP1-NFE2L2 pathway	Tamoxifen Staurosporine Dequalinium 13-Acetylphorbol Ingenol mebutate Benzoyl peroxide Fostamatinib
	SRPK2	SRSF protein kinase 2	Maturation of nucleoprotein	Adenine Purvalanol Phosphoaminophosphonic Acid-Adenylate Ester
	VAV1	vav guanine nucleotide exchange factor 1	GPVI-mediated activation cascade GPVI-mediated activation cascade PIP3 activates AKT signaling Signaling by SCF-KIT NRAGE signals death through JNK Regulation of actin dynamics for phagocytic cup formation Constitutive Signaling by Aberrant PI3K in Cancer FCERI mediated MAPK activation FCERI mediated Ca+2 mobilization FCERI mediated Ca+2 mobilization CD28 dependent Vav1 pathway G alpha (12/13) signalling events VEGFA-VEGFR2 Pathway VEGFA-VEGFR2 Pathway Interleukin-3, Interleukin-5 and GM-CSF signaling VEGFR2 mediated vascular permeability PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling RHOA GTPase cycle RAC1 GTPase cycle RAC2 GTPase cycle RHOG GTPase cycle Erythropoietin activates RAS Erythropoietin activates RAS Regulation of signaling by CBL FCGR3A-mediated phagocytosis FCGR3A-mediated phagocytosis Potential therapeutics for SARS Azathioprine ADME Antigen activates B Cell Receptor (BCR) leading to generation of second messengers Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
	ZAP70	zeta chain of T cell receptor associated protein kinase 70	Translocation of ZAP-70 to Immunological synapse Generation of second messenger molecules RHOH GTPase cycle Nuclear events stimulated by ALK signaling in cancer	Staurosporine Fostamatinib	Combined immunodeficiencies (CIDs), including the following nine diseases: X-linked hyper IgM syndrome; CD40 deficiency hyper IgM syndrome; Purine nucleoside phosphorylase (PNP) deficiency; Omenn syndrome; MHC deficiency (HLA-class I); MHC deficiency (HLA-class II); Zap-70 deficiency; p56 Lck deficiency; CD8 deficiency

Page 1 out of 1 pages